Update on Formulation of New Business Strategy - Seite 2

The new Executive Officers appointed by the board are Steven G. Sharabura - Interim Chief Executive Officer and Diana Zhabilov - Chief Financial Officer.

Steven G. Sharabura - Steve Sharabura holds a MBA from Cornell University and a Bachelor's Degree from Western University of Canada. For 35 years, Steve Sharabura has held roles in both corporate and entrepreneurial businesses. He has been the CEO at RobustoMed, an Enzolytics subsidiary for the past 3 years.

Diana Zhabilov - Diana Zhabilov holds a Master's degree in Science of Nursing from Medical University Sofia, Bulgaria. Mrs. Zhabilov successfully completed board certification in States of Texas and California as a Registered Nurse. Mrs. Zhabilov is able to communicate with people of all ages, and has over 25 years of experience in the nursing field, nursing administration, and education. In the year of 2000 Mrs. Zhabilov completed courses in accounting at Golden Gate University in San Francisco, California.

Steve Sharabura, Interim CEO stated, "The board and I have made progress and have narrowed our target acquisitions and markets to pursue our new business strategy. We have reached out to several entities as potential transaction candidates, including the possible acquisition of technologies previously developed by ENZC. We have also begun discussions for license agreements on a medical device for administering treatments and another diagnostic test for the detection of cancer. Along with the license opportunity, we are strongly leaning toward two targets that we feel will be a base for an aggressive start. In addition, we have contacted consultants to help us apply for the FINRA corporate action to start the process for the dividend of the SAGA shares received from the sale of the two operating subsidiaries."

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC.

While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics to identify acquisition targets and formulate a business strategy for implementation. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate.

Such forward-looking statements are based on current expectations. They involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release. The Company expressly disclaims any intention or obligation to update the forward-looking statements or update the reasons why actual results could differ from those projected in the forward-looking statements.

Company Contact:

Enzolytics, Inc.
1101 Raintree Circle
Allen, Texas 75013
www.enzolytics.com

SOURCE: Enzolytics, Inc.

View the original press release on accesswire.com


The Enzolytics Stock at the time of publication of the news with a raise of 0,00 % to 0,009USD on Nasdaq OTC stock exchange (12. April 2024, 02:10 Uhr).